1 minute read
Te Whatu Ora - Redeployment of Air Filtration Units- To Providers
Medicinal cannabis products that meet the minimum quality standard
Te Whatu Ora Redeployment of Air Filtration Units- To Providers
Advertisement
• The Misuse of Drugs (Medicinal Cannabis) Regulations 2019 (the
Regulations) set the minimum quality standard that medicinal cannabis products and ingredients must meet before they can be supplied in New Zealand. Importers, manufacturers, and suppliers must apply for assessment and provide evidence to the
Medicinal Cannabis Agency to verify that their products meet the minimum quality standard. • Medleaf Medium THC Afghan Haze has been verified as meeting the minimum quality standard. • More information on the products can be found on the Ministry of Health website Since February 2021, the Ministry of Health has purchased a number of Air Filtration Units (AFUs) to support the Managed Isolation and Quarantine Response. As these have now closed we have some units available that we can now offer to our Providers.
Information on the units:
o The units include an advanced HEPA filter to aid in providing additional air filtration support.
o These are IPC devices specifically designed to combine
HEPA filtration with a patented system of active 24/7/365 protection against a range of pathogens (viral & bacterial, also mould, fungi, endospores etc).
o ActivePure is the key technology in the units and is cleared by the FDA as a Class II medical device.
o The units are plug & play into a power source and very flexible – the units are being used across critical hygiene areas, corridors, rooms, operating theatres, ICU, ED, offices, staff break areas/lunch rooms, meeting rooms etc.
o The units need to be serviced & maintained on an annual cycle (all taken care of under the NZHP contract and
ActivePure staff throughout NZ).
These AFU’s provide air management support in line with WHO Guidelines for Ventilation for COVID-19, as well as the Supplementary standard issued by the Dental Council.
Link here to the WHO guidelines.
The distribution of these AFUs is being treated as a donation, with no associated capital costs or charges. There will however be an
